Symbio Pharmaceuticals Limited AI Stock Analysis
Want to see JP:4582 full AI Analyst Report?
Symbio Pharmaceuticals Limited (4582) AI Stock Analysis
Symbio Pharmaceuticals Limited
(TSE/TYO:4582)
The score is driven overwhelmingly by severe financial deterioration: collapsing revenue, a ¥4.8B net loss, -¥4.6B operating cash flow that exceeds remaining equity, and newly added debt against a shrinking balance sheet point to liquidity risk and possible dilutive financing or restructuring. Valuation offers no cushion, with negative earnings and no dividend. The only offsetting factor is near-term technical strength, with the price trading above its 20-, 50- and 100-day averages on positive MACD momentum, though it remains below the 200-day average. On balance, the speculative risk profile outweighs the recent price recovery.
Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.50M
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- -0.30
- Revenue Growth
- -30.58%
- EPS Growth
- 6.93%
- Country
- Japan
- Employees
- 91
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Symbio Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers...
Symbio Pharmaceuticals Limited Financial Statement Overview
Summary
Fundamentals are in distress across all three statements. Revenue collapsed 28% in FY2025 to ¥1.3B (down over 85% from the ¥10B 2022 peak), producing a ¥4.8B net loss and a -365% net margin despite healthy 72% gross margins. Equity has eroded to ¥1.3B from ¥4.2B a year earlier, with ¥2B of new debt (1.56x debt/equity) after years of being debt-free, and ROE at -375%. Operating and free cash flow of -¥4.6B exceeds the entire equity base, implying the cash cushion could be exhausted within a year absent dilutive financing or restructuring.
Income Statement
15Very NegativeBalance Sheet
28NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.06B | 1.31B | 2.45B | 5.59B | 10.01B | 8.25B |
| Gross Profit | 778.13M | 947.34M | 1.87B | 4.41B | 7.60B | 5.80B |
| EBITDA | -6.05B | -4.60B | -3.78B | -714.00M | 2.06B | 1.11B |
| Net Income | -6.09B | -4.78B | -3.83B | -1.96B | 1.18B | 2.03B |
Balance Sheet | ||||||
| Total Assets | 932.36M | 3.87B | 4.97B | 8.17B | 17.43B | 15.18B |
| Cash, Cash Equivalents and Short-Term Investments | 253.99M | 2.88B | 3.96B | 6.52B | 6.28B | 3.86B |
| Total Debt | 800.00M | 1.98B | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.23B | 2.60B | 770.77M | 8.14B | 8.92B | 8.43B |
| Stockholders Equity | -1.30B | 1.27B | 4.20B | 7.21B | 8.51B | 6.75B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -4.58B | -3.44B | -427.48M | 1.57B | 76.20M |
| Operating Cash Flow | 0 | -4.58B | -3.42B | -194.69M | 1.61B | 140.04M |
| Investing Cash Flow | 0 | -75.92M | -3.96M | -376.70M | -47.13M | -70.85M |
| Financing Cash Flow | 0 | 3.62B | 708.47M | 680.16M | 627.99M | -71.92M |
Symbio Pharmaceuticals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Positive. The current price of 69.00 is above the 20-day moving average (MA) of 57.05, above the 50-day MA of 55.70, and below the 200-day MA of 80.33, indicating a neutral trend. The MACD of 4.82 indicates Negative momentum. The RSI at 57.82 is Neutral, neither overbought nor oversold. The STOCH value of 64.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4582.
Symbio Pharmaceuticals Limited Peers Comparison
Overall Rating
JP:457469Neutral
JP:451252Neutral
JP:458648Neutral
JP:453946Neutral
JP:459739Underperform
JP:458237Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | JPY 12.72B | 29.01 | ― | 1.35% | 13.72% | -50.46% | |
| 52Neutral | JPY 10.03B | 53.95 | ― | 1.25% | 23.41% | 149.71% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | JPY 5.71B | -6.72 | ― | ― | -81.42% | 36.56% | |
| 46Neutral | JPY 5.70B | -11.69 | ― | 3.25% | 0.31% | -194.72% | |
| 39Underperform | JPY 7.10B | -8.55 | -53.06% | ― | 109.82% | 61.98% | |
| 37Underperform | JPY 7.87B | -0.76 | ― | ― | -30.58% | 6.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4582 | Symbio Pharmaceuticals Limited | 69.00 | -34.00 | -33.01% | |
| JP:4597 | Solasia Pharma KK | 26.00 | -5.00 | -16.13% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 280.00 | 6.31 | 2.30% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1540.00 | 59.18 | 4.00% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 244.00 | -50.00 | -17.01% | |
| JP:4586 | Medrx Co., Ltd. | 107.00 | -5.00 | -4.46% |
Symbio Pharmaceuticals Limited Corporate Events
SymBio Pharmaceuticals Swings to Deep Negative Equity as Losses Mount in 2026
SymBio Pharmaceuticals reported a sharp deterioration in its financial position for the first nine months of 2026, with net sales dropping 25.6% year-on-year to ¥722 million and losses deepening as operating profit fell to a ¥4,870 million deficit. T...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026
